- Bictegravir (BIC) + FTC/TAF and dolutegravir (DTG) + FTC/TAF both demonstrated high virologic response rates at W24 that were maintained at W48.
- No treatment-emergent resistance was detected in the BIC+FTC/TAF arm through W48.
Why this matters
- Because of their potency and...
You’ve reached the visitor articles limit
reserved for healthcare professionals
Already have an account? Login now